UK Markets close in 59 mins

Valneva SE (VNVLF)

YHD - YHD Delayed price. Currency in USD
Add to watchlist
0.00
As of 6:07PM EDT. Market open.
Full screen
Previous closeN/A
YTD returnN/A
Expense ratio (net)N/A
CategoryN/A
Last cap gainN/A
Morningstar ratingN/A
Morningstar risk ratingN/A
Sustainability ratingN/A
Net assetsN/A
Beta (5Y monthly)N/A
YieldN/A
5y average returnN/A
Holdings turnoverN/A
Last dividendN/A
Average for categoryN/A
Inception dateN/A
  • Globe Newswire

    Valneva Awarded FDA Breakthrough Designation for its Single-Shot Chikungunya Vaccine Candidate

    This new U.S. Milestone Follows FDA Fast Track and EMA PRIME Designations Saint Herblain (France), July 7, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration (FDA).

  • Globe Newswire

    Valneva Strengthens Management Team; Appoints Vincent Dequenne as SVP Operations and Joshua Drumm as VP Investor Relations

    Saint-Herblain (France), July 6, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it has appointed Vincent Dequenne as Senior Vice President Operations and Joshua Drumm as Vice President Investor Relations. Vincent Dequenne, engineer by training, has an extensive track record in the pharmaceutical industry with ov

  • Globe Newswire

    Valneva to Host Symposium on COVID-19 and Chikungunya Vaccine Candidates at 31st European Congress of Clinical Microbiology & Infectious Diseases

    Saint Herblain (France), July 5, 2021 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced today it will host a virtual symposium titled, “Developing new vaccines to protect against infectious diseases at home and abroad” on July 9, 2021 at 14:15 CEST at the 31st European Congress of Clinical Microbiology & Infectious Diseases (E